NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/22/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization21,945 mln
Float545 mln
Earnings Date08/17/2026
Beneish M-Score
-3.58
Highly reliable
1-Year Forecast
36.12
Attractive
Relative Strength
86
/ 100
Strongly outperforming
Debt / Equity
0.02
Debt-free
ROE
-6.75
Negative
Dividend Yield
0.00%
No dividend
Business Description
Roivant Sciences is a London-based biopharmaceutical company founded in 2014 that discovers, develops, and brings to market new medicines and drug delivery technologies. The company is advancing several treatment candidates targeting autoimmune and inflammatory conditions such as rheumatoid arthritis, lupus, and myasthenia gravis, as well as pulmonary hypertension linked to lung disease. Roivant also develops platforms designed to improve how medicines are delivered into the body.
